Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 8/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 5/20 | 0.53 |
| ▸ | CA7 | P43166 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13105226 | 0.87 | ALDH1A1 (0.60) | CA12CA9KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11118650 | 0.81 | DRD4 (0.58) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL9474175 | 0.80 | DRD4 (0.67) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL19286434 | 0.80 | GAA (0.54) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL27886642 | 0.79 | CA9 (0.61) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL34466955 | 0.77 | DRD4 (0.71) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL27524743 | 0.77 | GLA (0.55) | DRD4CA12CA9KDM4EALDH1A1 | |
| Methylamine SCHEMBL27532121 | 0.76 | GLA (0.51) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL22899134 | 0.75 | DRD4 (0.69) | DRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL3197214 | 0.75 | DRD4 (0.69) | DRD4CA12CA9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12152014-B2 | Therapeutic compounds and compositions | eXlthera Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024146906-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-07-11 | — | — | WO | disclosed |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3102200-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-108892661-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004103270-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-0484196-B1 | Novel derivatives of phosphonalcane polycarboxylic acids and use thereof | HOECHST FRANCE (FR) | 1995-06-21 | — | — | EP | disclosed |
| EP-0507930-B1 | MEASUREMENT OF COLOR REACTIONS BY MONITORING A CHANGE OF FLUORESCENCE | BAXTER DIAGNOSTICS INC (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5173434-A | Sandwiching a solution containing substance to be measured and chromogenic agent between a light source and an isolated fluorophore embedded in an inert light transmissive matrix and detecting change in flourophore emission | BAXTER DIAGNOSTICS INC. (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0507930-A1 | MEASUREMENT OF COLOR REACTIONS BY MONITORING A CHANGE OF FLUORESCENCE. | BAXTER DIAGNOSTICS INC (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992008123-A1 | MEASUREMENT OF COLOR REACTIONS BY MONITORING A CHANGE OF FLUORESCENCE | BAXTER DIAGNOSTICS INC. (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0484196-A1 | Novel derivatives of phosphonalcane polycarboxylic acids and use thereof | SOCIETE FRANCAISE HOECHST (FR) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | DRD4 4482/4885CA12 2336/4885CA9 1572/4885 |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | DRD4 4607/4885CA12 863/4885CA9 310/4885 |
| US-12152014-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | DRD4 4607/4885CA12 863/4885CA9 310/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | DRD4 4607/4885CA12 863/4885CA9 310/4885 |
| US-12084414-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | DRD4 4678/4885CA12 715/4885CA9 289/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | DRD4 4678/4885CA12 715/4885CA9 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.